IT Pro is supported by its audience. When you purchase through links on our site, we may earn an affiliate commission. Learn more

Sensome’s AI-powered stroke guidewire begins human trials in Australia

The trial adds to Sensome’s multicenter CLOT OUT study

Sensome has begun human trials for its artificial intelligence (AI)-powered stroke guidewire at the Gold Coast University Hospital (GCUH).

The trial will evaluate the safety and efficacy of the Sensome’s Clotild Smart Guidewire system in acute ischemic stroke patients. 

CLOT OUT is Sesome’s first-in-human, multicenter trial earmarked for leading stroke centers across Australia, Belgium, and France. The GCUH trial adds to this initiative. 

Replacing invasive medical procedures, Sensome’s Clotild Smart Guidewire system pairs impedance-based tissue sensors with machine learning algorithms to provide physicians with valuable insights into the clot.

The AI-powered system recently gained FDA approval to aid in treating or diagnosing life-threatening and irreversibly debilitating diseases and conditions.

“Endovascular thrombectomy is no longer just about removing the clot. To get the best result for your patient, you need to get the clot out with complete revascularization the first time,” explains Dr. Hal Rice, director of interventional neuroradiology at GCUH.

Rice added, “The Clotild guidewire is the first device that promises to provide live real-time information during the intervention that can help increase our chances to choose the right interventional approach from the get-go.”

Related Resource

Pharma transactions during the COVID-19 pandemic

How resilient were they?

Whitepaper front coverFree download

According to reports, Sensome aims to enroll up to 100 patients in its CLOT OUT study. Data from preliminary cases will be presented at this year's LINNC conference in Paris and at SLICE Worldwide, an online interactive stroke event.

“Evidence has been mounting over the past few years that factors like the biological clot composition should be considered when choosing the fastest method to remove a clot. The CLOT OUT trial aims to demonstrate that using Clotild in humans is safe and can detect clot composition,” stated Dr. Andrew Cheung, co-coordinating investigator of the study at Liverpool Hospital.

Featured Resources

Join the 90% of enterprises accelerating to the cloud

Business transformation through digital modernisation

Free Download

Delivering on demand: Momentum builds toward flexible IT

A modern digital workplace strategy

Free download

Modernise the workforce experience

Actionable insights and an optimised experience for both IT and end users

Free Download

The digital workplace roadmap

A leader's guide to strategy and success

Free Download

Recommended

The Total Economic Impact™ of IBM Watson Assistant
Whitepaper

The Total Economic Impact™ of IBM Watson Assistant

4 Jul 2022
AI for customer service
Whitepaper

AI for customer service

4 Jul 2022
Protecting healthcare from cybercrime
Whitepaper

Protecting healthcare from cybercrime

25 May 2022
Recommendations for managing AI risks
Whitepaper

Recommendations for managing AI risks

25 Apr 2022

Most Popular

Universities are fighting a cyber security war on multiple fronts
cyber security

Universities are fighting a cyber security war on multiple fronts

4 Jul 2022
Hackers claim to steal personal data of over a billion people in China
data breaches

Hackers claim to steal personal data of over a billion people in China

4 Jul 2022
Raspberry Pi launches next-gen Pico W microcontroller with networking support
Hardware

Raspberry Pi launches next-gen Pico W microcontroller with networking support

1 Jul 2022